摘要
近年来对于食管癌的治疗一直处于探索之中,关于晚期食管癌的治疗,仍以放化疗为主。尽管多种肿瘤的靶向治疗已取得了较大进展,但对食管癌的治疗疗效有限。针对免疫检查点的免疫治疗是一种新的抗肿瘤措施,免疫检查点抑制剂的运用,改善了食管癌患者预后,程序性死亡受体-1(PD-1)抑制剂潘利珠单抗、尼伏单抗、坎利珠单抗、辛替单抗在食管癌二线治疗上表现出了较好的疗效,免疫联合治疗策略也进展迅速,包括免疫联合化疗、免疫联合抗血管药物、免疫联合放化疗等。本文对近年来食管癌免疫治疗的研究进展进行综述。
In recent years,drug treatment for esophageal cancer has been under exploration.At present,the treatment of advanced esophageal cancer is still dominated by radiotherapy and chemotherapy.Although a variety of tumor targeted therapies have achieved significant results,there has been limited progress in the treatment of esophageal cancer.Immunotherapy for immune checkpoints is a new treatment measure.The use of immune checkpoint inhibitors has improved the prognosis of patients with esophageal cancer.The PD-1 inhibitors such as pembrolizumab,nivolumab,camrelizumab and sintilimab have shown good efficacy in the secondline treatment of esophageal cancer,and the immunization combined therapy strategies have also been rapidly developed,including the immune combined chemotherapy,immune combined anti-vascular drugs,and immune combined radiotherapy and chemotherapy.This article reviews the research progress in immunotherapy for esophageal cancer in recent years.
作者
李国雨
何明
LI Guo-yu;HE Ming(Hebei Medical University,Shijiazhuang 050000,China;Department of Thoracic Surgery,Hebei Medical University Fourth Hospital,Shijiazhuang 050000,China)
出处
《国际药学研究杂志》
CAS
北大核心
2020年第10期781-786,共6页
Journal of International Pharmaceutical Research
关键词
食管癌
免疫治疗
联合免疫治疗
免疫检查点抑制剂。
esophageal cancer
immunotherapy
combined immunotherapy
immune checkpoint inhibitors
